Related Experiment Video
Updated: Jun 27, 2026

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
Published on: November 26, 2018
[Arterial hypertension and cardiac arrhythmias]
1Abteilung Kardiologie, Evangelisches Krankenhaus Düsseldorf, Düsseldorf. kardiologie@evk-duesseldorf.de
Insights
Managing ventricular arrhythmias and atrial fibrillation involves addressing risk factors like hypertrophy and hypertension. Effective treatments include ACE inhibitors, beta-blockers, and in severe cases, implantable cardioverter-defibrillators or ablation.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Context:
- Ventricular arrhythmias and atrial fibrillation (AF) are significant causes of morbidity and mortality.
- Risk factors include left ventricular hypertrophy, fibrosis, ischemia, apoptosis, and arterial hypertension.
- Current therapeutic strategies aim to suppress arrhythmias, prevent sudden cardiac death, and manage underlying conditions.
Purpose:
- To review current therapeutic approaches for ventricular arrhythmias and atrial fibrillation.
- To highlight the efficacy and limitations of various antiarrhythmic drugs and interventions.
- To emphasize the importance of risk factor modification and personalized treatment strategies.
Summary:
- Ventricular arrhythmias are managed with ACE inhibitors, angiotensin receptor antagonists, beta-blockers, and in specific cases, implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy.
- Atrial fibrillation management focuses on risk factor control (hypertension, hypertrophy), rate control, and rhythm control strategies, including antiarrhythmic agents and catheter ablation.
- Class-1 antiarrhythmic drugs are generally contraindicated in left ventricular hypertrophy and heart failure; amiodarone has a role but is limited by side effects.
Impact:
- Optimized treatment strategies can reduce the risk of sudden cardiac death and improve survival in patients with arrhythmias.
- Understanding the role of specific drug classes and interventions allows for more tailored and effective patient care.
- Further research into novel antiarrhythmic therapies and ablation techniques may offer improved long-term outcomes.
Abstract:
VENTRICULAR ARRHYTHMIAS: Different factors--like hypertrophy, fibrosis, ischemia and apoptosis increase the risk of ventricular arrhythmias and sudden arrhythmic death. ACE inhibitors and Angiotensin receptor antagonists offer a curative therapeutic approach. Beta-blocker are strongly recommended. Amiodarone may be used for symptomatic arrhythmia suppression--but with no proven favourable prognostic effect. The use of class-1 antiarrhythmic drugs is obsolete in the presence of left ventricular hypertrophy and heart failure. Implantable cardioverter/defibrillators (ICD) have been proven to have a positive effect on survival in secondary and primary prevention of sudden cardiac death, and so has cardiac synchronization in severe cardiac dysfunction and widened QRS complex. Atrial fibrillation (AF): Arterial hypertension represents the main risk factor for AF. Patients' age, left ventricular hypertrophy, left atrial dilatation and angiotensin-II activation play an important role in the induction and maintenance of AF. Angiotensin-receptor and beta-blockers seem to be efficacious in AF suppression and also on the regression of hypertrophy. The use of antiarrhythmic agents (AA) is limited because of their relatively low long-term efficacy and pro-arrhythmia properties. Best results may be achieved with class 1C AA drugs in patients with no or minimal structural heart disease. In all other cases amiodarone is suitable but is limited by its side effects. In patients with no or only a few symptoms rate control may be sufficient, but if there are symptoms interventional left atrial ablation of pulmonary veins should be attempted as a real curative strategy.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Hypertension III: Clinical Manifestations and Diagnostic Studies
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Hypertension II: Pathophysiology
Dysrhythmias II: Classification of Tachyarrhythmias